Axsome’s stock falls after disclosing Teva’s plans to market generic Auvelity

Shares of Axsome Therapeutics Inc.
tumbled about 10.0% in premarket trading on Monday after the company said in a securities filing that Teva Pharmaceutical Industries Ltd.
is seeking approval from the Food and Drug Administration to market a generic version of Auvelity, Axsome’s depression treatment. Axsome’s stock has gained 95.8% over the past year, while the S&P 500
declined 7.6%.

Item 8.01 Other Events.

#Axsomes #stock #falls #disclosing #Tevas #plans #market #generic #Auvelity

About forextradingweb

Leave a Reply

Your email address will not be published. Required fields are marked *